OnPoint NYC’s supervised consumption site offers lifesaving harm reduction services, reversing 1,700 overdoses since 2021, but faces political headwinds.

By establishing coding and separate payment for certain digital mental health devices, this group from CMS and the FDA hopes to improve access to care.

Calorie labels on menus have a small but meaningful impact on people's choices, according to a new systematic review.

Medicare announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound

A new crop of companies is lining up to buy patient data from hospitals and sell it to those wanting to train AI or do research. 

A new study highlights the potential of a therapeutic strategy focused on stopping or slowing Huntington's disease.

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health care spending.

Under proposals from congressional Republicans, Medicaid would be transformed into a much more limited welfare program.

Over the last week, digital health startups with an AI focus have announced impressive fundraises, setting the tone for the rest of 2025.

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into trials.

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb their practices

Front-of-package labels have spurred companies in other countries to cut sugars and salt. The FDA wants to follow suit here.

The current head of the Center for Medicare has advice for her successor: "Engaging everyone in the ecosystem" is the foundation of good policymaking.

Seven ways to reinvest tariffs on medical items to create a strong and resilient health care supply chain.

Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large drugmakers

A bipartisan group of lawmakers is calling on the FTC to release an interim staff report on pharmacy benefit managers

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023

In an interview, outgoing FDA commissioner Robert Califf was wary of the Trump administration but unapologetic about controversial decision during his term.

Departing FDA leader Robert Califf defended the agency’s record and praised its progress on regulating food

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer patients.

The FDA published its first draft guidance on the use of AI in the development of drugs and biological products

Novo Nordisk filed another petition with the FDA seeking to block compounding pharmacies from making versions of one of its GLP-1 drugs

The alcohol industry relies on the myth of “responsible enjoyment” to downplay its products’ risks while spreading misinformation to stifle regulation.

Indian-Americans who remember life before the polio vaccine are worried about what RFK Jr. could do in the U.S.

After multiple short-term extensions, telehealth providers are eager for Congress to lay out its long-term plans for the sector.

U.S. senators and other lawmakers argue the problems created by UnitedHealth's size and reach demand steps to restore public confidence in the health care system

Novo Nordisk’s next-generation obesity candidate led to substantial weight loss in a pivotal study but fell short of expectations

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo